NLS Pharmaceutics Beta vs. Book Value Per Share
| NLSPW Stock | USD 0.01 0.01 83.33% |
For NLS Pharmaceutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NLS Pharmaceutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NLS Pharmaceutics AG utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NLS Pharmaceutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NLS Pharmaceutics AG over time as well as its relative position and ranking within its peers.
NLS |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NLS Pharmaceutics. If investors know NLS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NLS Pharmaceutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (2.28) |
The market value of NLS Pharmaceutics is measured differently than its book value, which is the value of NLS that is recorded on the company's balance sheet. Investors also form their own opinion of NLS Pharmaceutics' value that differs from its market value or its book value, called intrinsic value, which is NLS Pharmaceutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NLS Pharmaceutics' market value can be influenced by many factors that don't directly affect NLS Pharmaceutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NLS Pharmaceutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NLS Pharmaceutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NLS Pharmaceutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NLS Pharmaceutics Book Value Per Share vs. Beta Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NLS Pharmaceutics's current stock value. Our valuation model uses many indicators to compare NLS Pharmaceutics value to that of its competitors to determine the firm's financial worth. NLS Pharmaceutics AG is rated below average in beta category among its peers. It also is rated below average in book value per share category among its peers . At this time, NLS Pharmaceutics' Book Value Per Share is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value NLS Pharmaceutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NLS Book Value Per Share vs. Beta
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
NLS Pharmaceutics |
| = | -0.52 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
NLS Pharmaceutics |
| = | (9.40) X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
NLS Book Value Per Share Comparison
NLS Pharmaceutics is currently under evaluation in book value per share category among its peers.
Beta Analysis
As returns on the market increase, returns on owning NLS Pharmaceutics are expected to decrease at a much lower rate. During the bear market, NLS Pharmaceutics is likely to outperform the market.
NLS Pharmaceutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NLS Pharmaceutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NLS Pharmaceutics will eventually generate negative long term returns. The profitability progress is the general direction of NLS Pharmaceutics' change in net profit over the period of time. It can combine multiple indicators of NLS Pharmaceutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -158.1 K | -150.2 K | |
| Net Interest Income | -145.2 K | -152.4 K | |
| Interest Income | 505.9 K | 681.3 K | |
| Operating Income | -11.8 M | -12.4 M | |
| Net Loss | -12.2 M | -12.8 M | |
| Income Before Tax | -12.2 M | -12.8 M | |
| Total Other Income Expense Net | -365 K | -383.2 K | |
| Net Loss | -3.3 M | -3.5 M | |
| Net Loss | -12.2 M | -12.8 M | |
| Income Tax Expense | 1.80 | 1.71 | |
| Net Loss | (0.32) | (0.33) | |
| Income Quality | 0.80 | 0.52 |
NLS Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NLS Pharmaceutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NLS Pharmaceutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NLS Pharmaceutics' important profitability drivers and their relationship over time.
Use NLS Pharmaceutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.NLS Pharmaceutics Pair Trading
NLS Pharmaceutics AG Pair Trading Analysis
The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.
The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NLS Pharmaceutics position
In addition to having NLS Pharmaceutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Strategy ETFs Thematic Idea Now
Strategy ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Strategy ETFs theme has 1286 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Strategy ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.